Massachusetts Financial Services Co. MA Has $109.28 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Massachusetts Financial Services Co. MA reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 22.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 817,804 shares of the life sciences company's stock after selling 238,368 shares during the period. Massachusetts Financial Services Co. MA owned about 0.52% of Illumina worth $109,283,000 as of its most recent filing with the SEC.

• GRAIL: Biotech Stock Targeting $100B Cancer Market

A number of other institutional investors have also recently bought and sold shares of the business. Bleakley Financial Group LLC acquired a new stake in Illumina during the 4th quarter valued at $751,000. Zacks Investment Management bought a new position in Illumina in the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp lifted its position in Illumina by 17.5% during the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock worth $20,347,000 after acquiring an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in Illumina in the 4th quarter valued at $1,464,000. Finally, Allworth Financial LP grew its holdings in Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after buying an additional 6,263 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ILMN. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Stephens reissued an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and decreased their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Finally, Guggenheim cut their price target on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $140.90.

• Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Get Our Latest Research Report on ILMN

Illumina Stock Down 3.0 %

Shares of NASDAQ ILMN opened at $74.16 on Friday. Illumina, Inc. has a 52-week low of $70.64 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company's 50 day moving average price is $96.82 and its 200-day moving average price is $125.10. The company has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

• Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

• Five stocks we like better than Illumina
• 3 Grocery Stocks That Are Proving They Are Still Essential
• Archer Aviation’s Africa Deal Could Boost ACHR Stock
• How Investors Can Identify and Successfully Trade Gap-Down Stocks
• Are Short Sellers Wrong About These 3 Semiconductor Stocks?
• Why Are These Companies Considered Blue Chips?
• Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here